ETESEVIMAB

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Investigational

Approval Year

Substance Class	Protein Created by `admin` on `Wed Apr 02 07:12:07 GMT 2025` Edited by `admin` on `Wed Apr 02 07:12:07 GMT 2025`
Protein Type	MONOCLONAL ANTIBODY
Protein Sub Type	IGG1
Sequence Origin	HUMAN
Record UNII	N7Q9NLF11I
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LY-3832479

Preferred Name

English

ETESEVIMAB

Official Name

English

ANTI-SARS-COV-2 ANTIBODY JS016

Common Name

English

CB6

Code

English

JS016

Code

English

NP-005

Code

English

LY COV016

Code

English

LY3832479

Code

English

IMMUNOGLOBULIN G1*03-KAPPA, ANTI-(SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SPIKE GLYCOPROTEIN (PEPLOMER PROTEIN, E2))HUMAN MONOCLONAL ANTIBODY.GAMMA.1 HEAVY CHAIN (1-449) (HOMO SAPIENS VH (IGHV3-66*01 (97%) (IGHD)-IGHJ4*01 (93%)) (8.7.13) (1-119)-

Common Name

English

CB-6

Code

English

Etesevimab [WHO-DD]

Common Name

English

JS-016

Code

English

etesevimab [INN]

Common Name

English

ETESEVIMAB [USAN]

Common Name

English

IMMUNOGLOBULIN G1 (236-ALANINE,237-ALANINE), ANTI-(SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SPIKE GLYCOPROTEIN RECEPTOR-BINDING DOMAIN) (HUMAN MONOCLONAL JS016 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL JS016 .KAPPA.-CHAIN, DIMER

Common Name

English

IMMUNOGLOBULIN G1 (236-ALANINE,237-ALANINE), ANTI-(SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SPIKE GLYCOPROTEIN) (HUMAN MONOCLONAL LY3832479 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL LY3832479 .KAPPA.-CHAIN, DIMER

Common Name

English

NP005

Code

English

LY-COV016

Code

English

Code System Code Type Description

CAS

2423948-94-9

Created by admin on Wed Apr 02 07:12:07 GMT 2025 , Edited by admin on Wed Apr 02 07:12:07 GMT 2025

PRIMARY

INN

11873

Created by admin on Wed Apr 02 07:12:07 GMT 2025 , Edited by admin on Wed Apr 02 07:12:07 GMT 2025

PRIMARY

FDA UNII

N7Q9NLF11I

Created by admin on Wed Apr 02 07:12:07 GMT 2025 , Edited by admin on Wed Apr 02 07:12:07 GMT 2025

PRIMARY

RXCUI

2477854

Created by admin on Wed Apr 02 07:12:07 GMT 2025 , Edited by admin on Wed Apr 02 07:12:07 GMT 2025

PRIMARY

SMS_ID

300000026913

Created by admin on Wed Apr 02 07:12:07 GMT 2025 , Edited by admin on Wed Apr 02 07:12:07 GMT 2025

PRIMARY

NCI_THESAURUS

C173977

Created by admin on Wed Apr 02 07:12:07 GMT 2025 , Edited by admin on Wed Apr 02 07:12:07 GMT 2025

PRIMARY

DAILYMED

N7Q9NLF11I

Created by admin on Wed Apr 02 07:12:07 GMT 2025 , Edited by admin on Wed Apr 02 07:12:07 GMT 2025

PRIMARY

USAN

JK-03

Created by admin on Wed Apr 02 07:12:07 GMT 2025 , Edited by admin on Wed Apr 02 07:12:07 GMT 2025

PRIMARY

From	To
4_136	4_196
4_23	4_88
3_136	3_196
3_23	3_88
2_369	2_427
2_263	2_323
2_222	4_216
2_146	2_202
2_22	2_95
1_369	1_427
1_263	1_323
1_231	2_231
1_228	2_228
1_222	3_216
1_146	1_202
1_22	1_95

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_299
N	2_299

Related Record Type Details


					0EO1SV3LKY

SPIKE-1 PROTEIN SARS-COV-2

TARGET->LIGAND

Comments:

Blocks attachment of the virus to human angiotensin-converting enzyme 2 (ACE2) receptors, preventing subsequent viral entry into human cells and viral replication.

Amount:


					B6L4N5Z4GH

SARS-COV2

TARGET ORGANISM->INHIBITOR

Amount:

Related Record Type Details


					N7Q9NLF11I

ACTIVE MOIETY

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO ACID REMOVAL	[1_449] [2_449]	C-TERMINUS			LYSINE	K3Z4F929H6

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL
Molecular Formula	CHEMICAL